The expression of serum bile acid profile in patients with nonalcoholic fatty liver disease

Abstract

Abstract: Objective To explore the changes and application value of serum bile acid profile in patients with nonalcoholic fatty liver disease (NAFLD). Methods A total of 60 patients with NAFLD and 54 healthy individuals from Second Affiliated Hospital of Nanjing Medical University were enrolled between July 2019 and July 2020. Clinical data and blood samples were collected and high-performance liquid chromatography-mass spectrometry (LC-MS/MS) was used to determine 15 types of serum bile acid profile. Results Compared with healthy control group, the serum concentration of cholic acid (CA), chenodeoxycholic acid (CDCA), glycocholic acid (GCA) increased and lithocholic acid (LCA) decreased significantly in NAFLD group (P<0.05). There was no obvious differences in serum concentration of deoxycholic acid (DCA), ursodeoxy cholic acid (UDCA), glycolitho cholic acid (GLCA), glycodeoxy cholic acid(GDCA), glycochenodeoxy cholic acid (GCDCA), glycoursodeoxy cholic acid (GUDCA), taurocholic acid (TCA), taurolitho cholic acid (TLCA), taurodeoxy cholic acid (TDCA), taurochodeoxy cholic acid (TCDCA), tauroursodeoxy cholic acid (TUDCA) (P>0.05). In NAFLD group, the serum content of DCA, GCA, GDCA, GCDCA, TCA, TCDCA were positively correlated with the serum level of ALT and AST. BMI (OR: 1.615; 95%CI: 1.224-2.131; P<0.05) and LCA (OR: 0.946; 95%CI: 0.906-0.987; P<0.05) were both associated with the risk of NAFLD. Among the bile acid profile, CA (AUC: 0.640), CDCA (AUC: 0.617)and GCA (AUC:0.634) had the higher diagnostic value for NAFLD. Conclusion The serum bile acid profile in NAFLD patients is significantly changed,which suggests that it may have positive value in diagnosis of NAFLD.

Key words: Nonalcoholic fatty liver disease, Bile acid profile, Non-invasive diagnosis

ZHU Yue, QIAN Xiao-han, JI Guo-zhong, YANG Li-hua. The expression of serum bile acid profile in patients with nonalcoholic fatty liver disease[J]. Chinese Hepatolgy, 2021, 26(11): 1279-1282.

References

[1] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 2016, 64: 1388-1402.
[2] Yu Y, Cai J, She Z, et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases. Adv Sci (Weinh), 2019, 6: 1801585.
[3] Wong GL, Wong VW. How many deaths are caused by non-alcoholic fatty liver disease in the Asia-Pacific region? Lancet Gastroenterol Hepatol, 2020, 5: 103-105.
[4] Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med, 2017, 56: 34-44.
[5] Wang C, Zhu C, Shao L, et al. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm, 2019, 2019: 7659509.
[6] Gottlieb A, Canbay A. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression. Cells, 2019, 8: 1358.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版). 实用肝脏病杂志,2018,21: 177-186.
[8] Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci, 2019, 76: 1541-1558.
[9] Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut, 2018, 67: 1881-1891.
[10] Rao A, Kosters A, Mells JE, et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med, 2016, 8: 357ra122.
[11] Ferro D, Baratta F, Pastori D, et al. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients, 2020, 12: 2762.
[12] Jonas W, Schürmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab., 2020: 101111.
[13] Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut, 2017, 66: 180-190.
[14] Perino A, Demagny H, Velazquez-Villegas LA, et al. Molecular Physiology of Bile Acid Signaling in Health, Disease and Aging. Physiol Rev, 2021, 101:683-731.
[15] Aranha MM, Cortez-Pinto H, Costa A. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol, 2008, 20: 519-525.
[16] Nimer N, Choucair I, Wang Z, et al. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism, 2021, 116:154457.
[17] Jahnel J, Z?hrer E, Alisi A, et al. Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr, 2015, 61: 85-90.
[18] Yamada S, Kawaguchi H, Yamada T, et al. Cholic Acid Enhances Visceral Adiposity, Atherosclerosis and Nonalcoholic Fatty Liver Disease in Microminipigs. J Atheroscler Thromb, 2017, 24: 1150-1166.